<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01005407</url>
  </required_header>
  <id_info>
    <org_study_id>DV2-HBV-16</org_study_id>
    <nct_id>NCT01005407</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine</brief_title>
  <official_title>An Observer-Blinded, Randomized, Parallel-Group, Multi-Center Study Comparing the Safety and Immunogenicity of HEPLISAV™ to Licensed Vaccine (Engerix-B®) Among Healthy Subjects 40 to 70 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dynavax Technologies Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dynavax Technologies Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety, immunogenicity and lot-to-lot consistency
      of an investigational hepatitis B virus vaccine, HEPLISAV™, in healthy adults 40 to 70 years
      of age
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to evaluate the safety, immunogenicity and lot-to-lot consistency
      of an investigational hepatitis B virus vaccine, HEPLISAV™, in healthy adults 40 to 70 years
      of age
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Who Have a Seroprotective Immune Response</measure>
    <time_frame>at Week 12 and at Week 32</time_frame>
    <description>Percentage of subjects who have a seroprotective immune response (anti-HBsAg antibody≥ 10 milli-international unit (mIU)/mL) 8 weeks after the last active dose of HEPLISAV™ compared to 8 weeks after the last active dose of Engerix-B®</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Local and Systemic Reaction to Injections</measure>
    <time_frame>within 7 days for post-injection reactions</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2452</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>HEPLISAV and/or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Engerix-B(1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.0 mL Engerix-B</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HEPLISAV and/or Placebo</intervention_name>
    <description>Intramuscular (IM) injections on Week 0 and Week 4; placebo (saline) injection at Week 24</description>
    <arm_group_label>HEPLISAV and/or Placebo</arm_group_label>
    <other_name>Hepatitis B vaccine (recombinant), adjuvanted</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Engerix-B</intervention_name>
    <description>Intramuscular (IM) injections on Week 0, Week 4 and Week 24</description>
    <arm_group_label>Engerix-B(1)</arm_group_label>
    <other_name>Hepatitis B vaccine (recombinant)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  be 40 - 70 years of age, inclusive

          -  be seronegative for hepatitis B surface antigen (HBsAg), antibody against hepatitis B
             surface antigen (anti-HBsAg), antibody against hepatitis B core antigen (anti-HBcAg),
             and human immunodeficiency virus (HIV)

          -  be in good health in the opinion of the investigator, based upon medical history,
             physical examination, and laboratory evaluation

          -  if female of childbearing potential, agree to consistently use a highly effective
             method of birth control from screening visit through the treatment phase, for up to 28
             days after the last injection

        Exclusion Criteria:

          -  if female of childbearing potential, is pregnant, breastfeeding, or planning a
             pregnancy

          -  has a history of or is considered by the investigator to be at high risk for recent
             exposure to HBV or HIV; for example, current intravenous drug use or has unprotected
             sex with known HBV/HIV positive partner

          -  has a known history of autoimmune disease

          -  has previously received any hepatitis B vaccine (approved or investigational)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn Center</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grove City</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jefferson Hills</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Upper Saint Clair</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mount Pearl</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2009</study_first_submitted>
  <study_first_submitted_qc>October 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2009</study_first_posted>
  <results_first_submitted>December 8, 2017</results_first_submitted>
  <results_first_submitted_qc>December 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 11, 2018</results_first_posted>
  <disposition_first_submitted>June 16, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>June 16, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 19, 2014</disposition_first_posted>
  <last_update_submitted>January 15, 2018</last_update_submitted>
  <last_update_submitted_qc>January 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HBV vaccine</keyword>
  <keyword>Hepatitis B vaccine</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>Hepatitis</keyword>
  <keyword>HBV</keyword>
  <keyword>Prevention &amp; Control</keyword>
  <keyword>Healthy</keyword>
  <keyword>Healthy volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HEPLISAV and/or Placebo</title>
          <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
HEPLISAV and/or Placebo: Intramuscular (IM) injections at Week 0, Week 4, plus a placebo (saline) injection at Week 24</description>
        </group>
        <group group_id="P2">
          <title>Engerix-B</title>
          <description>1.0 mL Engerix-B
Engerix-B: Intramuscular injections at Week 0, Week 4, and Week 24</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1969"/>
                <participants group_id="P2" count="483"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1818"/>
                <participants group_id="P2" count="451"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population: All participants who received at least 1 study injection and who had any post-baseline safety data</population>
      <group_list>
        <group group_id="B1">
          <title>HEPLISAV and Placebo</title>
          <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
HEPLISAV and/or Placebo: Intramuscular (IM) injections at Week 0, Week 4, plus a placebo (saline) injection at Week 24</description>
        </group>
        <group group_id="B2">
          <title>Engerix-B</title>
          <description>1.0 mL Engerix-B
Engerix-B: Intramuscular (IM) injections on Week 0, Week 4 and Week 24</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1968"/>
            <count group_id="B2" value="481"/>
            <count group_id="B3" value="2449"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>≥ 40 to ≤ 70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1968"/>
                    <measurement group_id="B2" value="481"/>
                    <measurement group_id="B3" value="2449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1025"/>
                    <measurement group_id="B2" value="245"/>
                    <measurement group_id="B3" value="1270"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="943"/>
                    <measurement group_id="B2" value="236"/>
                    <measurement group_id="B3" value="1179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1817"/>
                    <measurement group_id="B2" value="436"/>
                    <measurement group_id="B3" value="2253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Who Have a Seroprotective Immune Response</title>
        <description>Percentage of subjects who have a seroprotective immune response (anti-HBsAg antibody≥ 10 milli-international unit (mIU)/mL) 8 weeks after the last active dose of HEPLISAV™ compared to 8 weeks after the last active dose of Engerix-B®</description>
        <time_frame>at Week 12 and at Week 32</time_frame>
        <population>Non-Inferiority per Protocol population:Randomized subjects who received 1 of 3 consistency lots of HEPLISAV or Engerix-B within the study visit windows, had all 3 study injections as randomized and within the study visit windows, no major protocol deviations, and anti-HBs levels obtained within study visit windows at baseline, Week 12, and Week 32</population>
        <group_list>
          <group group_id="O1">
            <title>HEPLISAV and Placebo</title>
            <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
HEPLISAV and/or Placebo: Intramuscular (IM) injections at Week 0, Week 4, plus a placebo (saline) injection at Week 24</description>
          </group>
          <group group_id="O2">
            <title>Engerix-B</title>
            <description>1.0 mL Engerix-B
Engerix-B: Intramuscular (IM) injections on Week 0, Week 4 and Week 24</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Have a Seroprotective Immune Response</title>
          <description>Percentage of subjects who have a seroprotective immune response (anti-HBsAg antibody≥ 10 milli-international unit (mIU)/mL) 8 weeks after the last active dose of HEPLISAV™ compared to 8 weeks after the last active dose of Engerix-B®</description>
          <population>Non-Inferiority per Protocol population:Randomized subjects who received 1 of 3 consistency lots of HEPLISAV or Engerix-B within the study visit windows, had all 3 study injections as randomized and within the study visit windows, no major protocol deviations, and anti-HBs levels obtained within study visit windows at baseline, Week 12, and Week 32</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1121"/>
                <count group_id="O2" value="353"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.1"/>
                    <measurement group_id="O2" value="70.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Local and Systemic Reaction to Injections</title>
        <time_frame>within 7 days for post-injection reactions</time_frame>
        <population>Safety population: All participants who received at least 1 study injection and had at least 1 post-baseline safety data. NOTE: Only subjects with non-missing injection results in the Safety population are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>HEPLISAV and Placebo</title>
            <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
HEPLISAV and/or Placebo: Intramuscular (IM) injections at Week 0, Week 4, plus a placebo (saline) injection at Week 24</description>
          </group>
          <group group_id="O2">
            <title>Engerix-B</title>
            <description>1.0 mL Engerix-B
Engerix-B: Intramuscular (IM) injections on Week 0, Week 4 and Week 24</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Local and Systemic Reaction to Injections</title>
          <population>Safety population: All participants who received at least 1 study injection and had at least 1 post-baseline safety data. NOTE: Only subjects with non-missing injection results in the Safety population are included in this analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1952"/>
                <count group_id="O2" value="477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Local reaction: Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.33"/>
                    <measurement group_id="O2" value="18.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local reaction: Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.10"/>
                    <measurement group_id="O2" value="16.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local reaction: Injection 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="13.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic reaction: Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.34"/>
                    <measurement group_id="O2" value="22.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic reaction: Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.38"/>
                    <measurement group_id="O2" value="18.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic reaction: Injection 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="13.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events were assessed for the safety analysis population: All participants who received at least 1 study injection and had a least 1 post baseline safety data</desc>
      <group_list>
        <group group_id="E1">
          <title>HEPLISAV and/or Placebo</title>
          <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
HEPLISAV and/or Placebo: Intramuscular (IM) injections at Week 0, Week 4, plus a placebo (saline) injection at Week 24</description>
        </group>
        <group group_id="E2">
          <title>Engerix-B(1)</title>
          <description>1.0 mL Engerix-B
Engerix-B: Intramuscular (IM) injections on Week 0, Week 4 and Week 24</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Barrett's oesophagus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cavernous sinus thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Delayed recovery from anaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Water intoxication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Loose body in joint</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Colon cancer stage iv</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Inflammatory carcinoma of the breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Benign intracranial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Spondylitic myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Haemorrhagic ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="1968"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Janssen MD \ VP &amp; Chief Medical Officer</name_or_title>
      <organization>Dynavax Technologies, Inc.</organization>
      <phone>510-848-5100</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

